Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Status:
Completed
Trial end date:
2008-01-24
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, prospective, Phase III study in which patients with
advanced breast carcinoma previously treated with anthracyclines and taxanes will be randomly
assigned to receive one of two treatment options: vinorelbine (Arm A) or gemcitabine plus
vinorelbine (Arm B).